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(N¼124) or MDS (N¼41) following a similar conditioning
regimen but for the dose of busulfan (Bu): 1/Fludarabine (30
mg/m2/day over 5 days) 2/, rabbit ATG (r-ATG) (2.5mg/kg/day
over 2 days) and 3/ i.v. or oral Busulfan (Bu) (130 mg/m2/day
or 3.2 mg/kg respectively over 2 to 4 days) (table 1). Cyclo-
sporin A was given as post graft immunosuppression.
Initially higher Bu doses were proposed to patients under the
age of 55, without comorbidities and with higher risk
diseases.
Results: With a median follow up of 20.7 months, 2 year
overall survival (OS) and PFS were 59.6% (95% CI: 51.8-68.6)
and 54.9% (95% CI: 47-64) respectively. Grade 2-4 and 3-4
acute graft-versus-host diseases (aGvhD) at day 100 was
19.4% and 7.9% respectively. cGvhD (all grades) and extensive
cGvhD were 25% and 14.4% at 1 year post transplantation
respectively. Non relapsemortality (NRM)was 11.7 and 15.4%
at 12 and 24 months. Relapse (CIR) was 24% and 29.7% at 1
and 2 years.
Overall neither the patient age, nor the donor type or the
dose of Busulfan inﬂuenced signiﬁcantly OS, PFS or CIR in the
whole cohort. Surprisingly, NRM was lower after 3 or 4 days
busulfan conditioning regimen (3.6% vs 21.3%,P ¼ .009).
The 93 CR1 AML patients had 2-year OS and PFS of 63.4%
(95% CI: 53.3-75.3) and 60.9% (95%CI: 50.8-72.9) respectively.
Two-year OS reached 66.4% (95%CI: 56.4-81.8) for AML
patients with favorable or intermediate karyotype and 50.5%
(95%CI: 33-77.3) for unfavorable, P ¼ .08. AML patients with
favorable or intermediate karyotype tend to have a better
2-year PFS (63.8%, 95%CI: 52.2-78.1) than unfavorable
karyotype (52%, 95%CI: 34.5-78.3), P ¼ .2.
Patients under the age of 55 (n¼76) present overall
a better outcome than older (OS: 63.9 (CI: 52.7-74.4) vs 56%
(CI: 45.6-68.7), P ¼ .2, PFS: 60.5 (49.7-73.8) vs 50.4% (CI: 40-
63.5),P ¼ .2, NRM: 9.4 vs 20.3%, P ¼ .07). In addition higher
doses of BU improved OS (77.5% vs 47.9%, P ¼ .058), PFS (71.6
vs 46.4%, P ¼ .1), without increase of NRM (2.2% vs 18.7%,
P ¼ .03).
Conclusion: This conditioning regimen using Fludarabin,
Busulfan and r-ATG can result in good OS and PFS probabil-
ities, in myeloid malignancies. Given the patient population
characteristics the NRM can be considered as low. The good
NRM proﬁle of higher doses invite to further developments.347
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Aim: To determine the safety and feasibility of using G-CSF-
mobilized peripheral blood progenitor cells from hap-
loidentical related donors for transplantation in patients
with poor-risk hematological malignancies receiving
reduced intensity conditioning therapy and post-transplant
cyclophosphamide as GVHD prophylaxis.
Methods: Nine patients aged 33 to 65 years (median 48)
with poor prognosis hematological malignancies (4 AML, 1
MDS, 2 Ph+ ALL, 1 DLBCL, 1 ALL) who lacked HLA-matchedrelated or unrelated donors underwent transplantation using
G-CSF-mobilized PBSC from haploidentical relatives, after
receiving reduced intensity conditioning therapy with ﬂu-
darabine, cyclophosphamide, and single fraction TBI 200 cGy.
GVHD prophylaxis consisted of cyclophosphamide 50 mg/kg
IV daily on days +3 and +4, followed by daily oral tacrolimus
and mycophenolate. Median follow-up is 11 months (1-14).
Results were compared with a previous cohort of 12 patients
receiving unmanipulated haploidentical bone marrow.
Results: Neutrophil and platelet recovery (ANC >1.0 median
day 18, range 11-35 ; platelets >20 median day 19, 1-45) was
comparable with 15 and 17 days respectively,for bone
marrow. Six patients had neutropenic fevers, but there was
no mucositis, use of TPN, or early transplant-related death.
Six of 8 assessable patients had complete donor chimerism in
blood T cells and granulocytes at day +28. Two had graft
rejection with only host DNA (one patient with MDS with
high-titre anti-donor HLA antibodies, and one patient with
ALL), as compared with 2 rejections of 12 previous patients
receiving bone marrow grafts. Of the 6 patients with
complete donor chimerism, 1 had stage 3 skin acute GVHD,
but there has been no chronic GVHD or disease relapse. The
MDS patient with graft rejection was re-transplanted after
plasmapheresis and rituximab and IV cyclophosphamide/
busulphan conditioning with PBSC from an alternative hap-
loidentical related donor, and identical GVHD prophylaxis,
and achieved complete donor chimerism.
Conclusion: The use of unmanipulated G-CSF-mobilized
HPC collected from haploidentical relatives appears feasible
for patients receiving reduced intensity conditioning and
high-dose cyclophosphamide as GVHD prophylaxis, with
rates of engraftment, graft rejection and GHVD comparable
to that seen with haploidentical bone marrow. This protocol
offers an allogeneic transplant option with low cost and
toxicity for patients without a HLA-identical donor.348
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Introduction: Liver biopsy might be necessary in the diag-
nosis of liver dysfunction after allogeneic stem cell trans-
plantation (allo-SCT) but transparietal (TP) access is usually
not possible. Transjugular liver biopsies (TJLB) may offer
a good alternative. We retrospectively analyzed the role of
TJLB in the diagnosis of early hepatic dysfunction after allo-
SCT.
Methods: We included all consecutive allo-SCT recipients
undergoing TJLB in our centre from May 1997 to September
2011. Median follow-up for survivors was 28 months (1-57).
According to our protocol, TJLB instead of TP access was
preferred in patients with platelet count <50x10e9/L, coag-
ulation abnormalities or unstable medical condition. TJLB
were performed using a needle coated with a ﬂexible cath-
eter through jugular access. Pathological samples were
analyzed by an experienced pathologist in the centre and
retrospectively revised.
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performed in our center. A total of 22 patients (14%) under-
went 24 TJLB procedures at a median of 38 days (12-152)
after transplant. Median age was 29 years (range 17-64).
Most patients receivedmyeloablative allo-SCT (n¼18)mainly
for AML (n¼6). Transjugular route was chosen because of
thrombocytopenia (n¼12, 50%), coagulation abnormalities
(n¼2, 8.3%) or both (n¼10, 41%). Clinical suspicions before
TJLB were hepatic sinusoidal obstructive syndrome (SOS)
(n¼12, 50%) and GVHD (n¼12, 50%). The biopsy allowed
a diagnosis in 17 cases (70%) including: iron overload/
cholestatic liver disease (n¼8), liver GVHD (n¼4), HSOS
(n¼3), and one case each of cholangitis lenta and CMV
hepatitis (n¼2). Main clinical suspicion was conﬁrmed after
biopsy in 5 (21%) cases while in 12 (50%) it revealed another
initial diagnosis suspected and supposed a change of thera-
peutic approach in 8 (33%) of them. Seven (29%) biopsies
were non-diagnostic, 5 due to unspeciﬁc ﬁndings and 2
because of insufﬁcient sample size. Although commonly
TJLB-related complications were mild, mainly subcutaneous
hematoma (n¼3, 12.5%) there also was one TJLB-related
death because of severe bleeding. In summary, TJLB allowed
for the identiﬁcation of a cause of liver abnormality in 70% of
our patients, including 33% in which the diagnosis implied
a change in the therapy. It may be a helpful tool in the
diagnosis of liver abnormalities, with moderate toxicity but
not risk-free.349
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Background: Hemophagocytic lymphohistiocytosis (HLH),
a group of immunodeﬁciency disorder characterized by
defective lymphocyte cytotoxicity and immune dysregula-
tion leading to hyper inﬂammatory state. If untreated, this
condition is potentially fatal. Currently, allogeneic hemato-
poietic cell transplantation (HCT) is the only deﬁnitive
curative therapy for HLH. Recently, with increased aware-
ness, HLH is being diagnosed in adults. However, there is
very limited data on HCT outcome for adults with HLH. Here
we report our experience of allogeneic HCT for HLH in adults
(18 years).
Methods: We retrospectively analyzed the outcomes of 10
adult patients with HLH (7 male and 3 female) who had
undergone allogeneic HCT between January 2004 and
September 2012 in our institution. Genetic diagnosis was
made in 4 patients (2 perforin defect, one MUNC 13-4, one
XIAP). CNS involvement at diagnosis was noted in 5 patients,
all of them received some form of induction therapy based
on HLH-2004 protocol, and at the time of transplant HLHwas
well controlled in seven patients. The median age at trans-
plantation was 20.2 years (range: 18.1-27.2). Majority (9/10)
underwent reduced-intensity conditioning (RIC) regimen
consisting of alemtuzumab, ﬂudarabine, and melphalan. One
underwent myeloablative preparative regimen consisting of
busulfan, cyclophosphamide, and ATG. Nine patients
received transplants fromHLA-matched donors (8-MUD and
1 MSD). Bone marrow was the source of stem cell in seven
patients and PBSC in another three. In most patients (9/10)
cyclosporine and prednisone was used as GvHD prophylaxis.Result: Overall survival was 50% (5/10) at a median follow-
up of 17 months post-transplant (range: 6 -82). In patients
who received RIC the survival was 56% (5/9). The median
time for neutrophil engraftment was 11 days (range: 9-15).
Grade II to IV acute GvHD developed in two patients. Mixed
donor chimerism was noted in 33% (3/9) of patients who
received RIC. Of the ﬁve patients who died one died prior to
engraftment on day 9, and other on day 45, three other died
after day+ 100(range: 193 -324). The cause of death was
bacterial sepsis with multi-organ failure in three patients,
and acute gut GvHD with intestinal perforation and candi-
demia in one, and progressive necrotizing leukoencephal-
opathy in another. Of the surviving ﬁve patients, NK cell
function had normalized in all of them and none have
developed chronic GvHD.
Conclusion: Overall survival of 56% with RIC in young adults
with HLH is lower than the 88% survival reported in patients
less than 18 years of age from our center (P < .05). Prospec-
tive multicenter study is warranted to validate the present
ﬁnding, and also better identify the risk factors in adults to
improve HCT outcome for HLH.350
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The optimal treatment for relapsed acute promyelocytic
leukemia (APL) in pediatric patients is controversial. Allo-
geneic hematopoietic stem cell transplantation is an alter-
native for consolidation therapy for these patients, with
published event-free survival rates of 70-75%. We report
a pediatric patient with acute promyelocytic leukemia (APL)
who relapsed 28 months after cord blood transplantation
from her sibling and then successfully treated with bone
marrow transplantation from the same donor after rein-
duction. First relapse occurred at 2 years of age, 4 months
after induction therapy with ATRA, cytarabine and dauno-
rubicin, during consolidation with ATRA and adriamycin.
Sibling donor matched cord blood transplantation was
performed after successful reinduction with arsenic
trioxide, using myeloablative conditioning regimen with
busulfan and cyclophosphamide and cyclosporine for GVHD
prophylaxis. Second relapse was also treated with arsenic
trioxide, and matched sibling bone marrow transplant from
the same donor 32 months after the cord blood transplant,
using conditioning with TBI, cytarabine and cyclophospha-
mide and low level cyclosporine prophylaxis. Chronic skin
GVHD with moderate scleroderma has developed, currently
under control, and this patient is now with no evidence of
malignancy and persistent molecular remission at 40
months post-second transplantation, approximately 6 years
and 8 months from diagnosis. This case report demon-
strates the role of graft-versus-leukemia activity in APL and
vividly illustrates the role of different cell sources from
same donor in allogeneic transplantation for pediatric
patients.
